NCT02444091View on ClinicalTrials.gov

Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
Chronic Fatigue Syndrome (CFS)Myalgic Encephalomyelitis (ME)
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.

Trial Locations (1)

N-5021

Dept. of Oncology, Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

The Kavli Foundation

UNKNOWN

collaborator

Oslo University Hospital

OTHER

lead

Haukeland University Hospital

OTHER

NCT02444091 - Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) | Biotech Hunter | Biotech Hunter